Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) Assets Average (2019 - 2025)

Allogene Therapeutics' Assets Average history spans 7 years, with the latest figure at $455.2 million for Q3 2025.

  • For Q3 2025, Assets Average fell 26.35% year-over-year to $455.2 million; the TTM value through Sep 2025 reached $455.2 million, down 26.35%, while the annual FY2024 figure was $595.8 million, 18.63% down from the prior year.
  • Assets Average for Q3 2025 was $455.2 million at Allogene Therapeutics, down from $489.3 million in the prior quarter.
  • Across five years, Assets Average topped out at $1.2 billion in Q1 2021 and bottomed at $455.2 million in Q3 2025.
  • The 5-year median for Assets Average is $758.9 million (2023), against an average of $795.9 million.
  • The largest annual shift saw Assets Average surged 71.15% in 2021 before it fell 26.35% in 2025.
  • A 5-year view of Assets Average shows it stood at $1.1 billion in 2021, then dropped by 19.44% to $858.0 million in 2022, then decreased by 20.97% to $678.1 million in 2023, then decreased by 16.1% to $568.9 million in 2024, then dropped by 19.99% to $455.2 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Assets Average are $455.2 million (Q3 2025), $489.3 million (Q2 2025), and $528.3 million (Q1 2025).